http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112457293-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 2020-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112457293-B |
| titleOfInvention | Use of TBTU in the preparation of anticancer drugs |
| abstract | The invention provides a use of TBTU in the preparation of anticancer drug lorlatinib, which is characterized by comprising the following steps: dissolving the compound of formula A in an organic solvent, adding a condensing agent TBTU and an alkali accelerator DBU, and stirring until uniform , the system was heated to 40-60 °C, and the reaction was kept for 2-3 h. After the TLC detection was completed, the reaction was cooled to room temperature, ammonium chloride solution was added to quench the reaction, and lorlatinib was obtained after extraction and separation; The structural formula of compound A is The present invention uses TBTU as the condensing agent and DBU as the alkali accelerator, and the two are used in combination. Compared with the prior art, the usage amount of the condensing agent and the alkali accelerator used in the present invention is obviously reduced, the reaction time is shorter, but the reaction yield However, it is much larger than the existing technology and is very suitable for industrial production. |
| priorityDate | 2020-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.